| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 70 | 2024 | 195 | 22.760 |
Why?
|
| Tuberculosis | 46 | 2024 | 121 | 17.160 |
Why?
|
| Tuberculosis, Pulmonary | 25 | 2024 | 58 | 7.180 |
Why?
|
| Interleukin-17 | 26 | 2020 | 105 | 5.360 |
Why?
|
| Tuberculosis Vaccines | 11 | 2024 | 17 | 4.720 |
Why?
|
| Lung | 38 | 2024 | 1258 | 4.380 |
Why?
|
| Immunity, Innate | 18 | 2024 | 429 | 3.430 |
Why?
|
| Latent Tuberculosis | 13 | 2022 | 16 | 3.430 |
Why?
|
| Th17 Cells | 13 | 2020 | 84 | 3.300 |
Why?
|
| BCG Vaccine | 8 | 2024 | 34 | 2.620 |
Why?
|
| Rifampin | 6 | 2024 | 23 | 2.530 |
Why?
|
| Cytokines | 15 | 2024 | 801 | 2.520 |
Why?
|
| Interleukin-23 | 12 | 2019 | 57 | 2.500 |
Why?
|
| Dendritic Cells | 13 | 2020 | 440 | 2.310 |
Why?
|
| Animals | 100 | 2024 | 27280 | 2.240 |
Why?
|
| Mice | 59 | 2024 | 11724 | 2.230 |
Why?
|
| Mice, Knockout | 31 | 2024 | 1990 | 2.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2021 | 442 | 2.160 |
Why?
|
| Mice, Inbred C57BL | 40 | 2024 | 3204 | 2.080 |
Why?
|
| Interleukins | 12 | 2022 | 129 | 2.040 |
Why?
|
| Macrophages | 12 | 2022 | 571 | 2.000 |
Why?
|
| Calgranulin B | 4 | 2023 | 16 | 2.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 8 | 2023 | 135 | 1.980 |
Why?
|
| Granuloma | 12 | 2022 | 65 | 1.900 |
Why?
|
| DNA-Directed RNA Polymerases | 4 | 2024 | 103 | 1.880 |
Why?
|
| Lymphoid Tissue | 8 | 2023 | 57 | 1.880 |
Why?
|
| Vaccines | 4 | 2024 | 82 | 1.870 |
Why?
|
| Interferon Type I | 4 | 2024 | 178 | 1.780 |
Why?
|
| Signal Transduction | 17 | 2024 | 3370 | 1.750 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2021 | 104 | 1.700 |
Why?
|
| Bacterial Proteins | 8 | 2024 | 887 | 1.620 |
Why?
|
| Mycobacterium bovis | 5 | 2024 | 16 | 1.620 |
Why?
|
| Interleukin-12 | 7 | 2019 | 109 | 1.580 |
Why?
|
| Influenza, Human | 4 | 2022 | 336 | 1.530 |
Why?
|
| Chemokines | 5 | 2020 | 74 | 1.510 |
Why?
|
| Immunity, Mucosal | 7 | 2020 | 69 | 1.490 |
Why?
|
| Chemokine CXCL13 | 7 | 2019 | 15 | 1.440 |
Why?
|
| Lymphocyte Activation | 9 | 2021 | 751 | 1.330 |
Why?
|
| Calgranulin A | 4 | 2023 | 11 | 1.320 |
Why?
|
| Th1 Cells | 8 | 2021 | 166 | 1.300 |
Why?
|
| Host-Pathogen Interactions | 5 | 2021 | 236 | 1.300 |
Why?
|
| Francisella tularensis | 4 | 2013 | 9 | 1.290 |
Why?
|
| Neutrophil Infiltration | 5 | 2020 | 28 | 1.290 |
Why?
|
| Inflammation | 10 | 2024 | 970 | 1.270 |
Why?
|
| Mycobacterium Infections | 3 | 2019 | 15 | 1.220 |
Why?
|
| Vaccination | 8 | 2024 | 273 | 1.180 |
Why?
|
| Chemokines, CXC | 3 | 2021 | 22 | 1.140 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 8 | 2022 | 18 | 1.130 |
Why?
|
| Bacterial Infections | 2 | 2023 | 184 | 1.120 |
Why?
|
| Mucous Membrane | 4 | 2017 | 83 | 1.100 |
Why?
|
| Coinfection | 11 | 2022 | 61 | 1.100 |
Why?
|
| Killer Cells, Natural | 5 | 2022 | 275 | 1.090 |
Why?
|
| Humans | 85 | 2024 | 88946 | 1.080 |
Why?
|
| Phagocytes | 1 | 2024 | 11 | 0.970 |
Why?
|
| CD11c Antigen | 1 | 2024 | 13 | 0.970 |
Why?
|
| Interleukin-12 Subunit p40 | 6 | 2020 | 12 | 0.960 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2024 | 299 | 0.950 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2024 | 6 | 0.950 |
Why?
|
| Cell Movement | 8 | 2019 | 783 | 0.920 |
Why?
|
| Saponins | 1 | 2024 | 42 | 0.920 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 12 | 0.900 |
Why?
|
| Macaca mulatta | 22 | 2022 | 466 | 0.880 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2013 | 275 | 0.840 |
Why?
|
| Adjuvants, Immunologic | 4 | 2024 | 168 | 0.840 |
Why?
|
| Biomarkers | 6 | 2024 | 1754 | 0.830 |
Why?
|
| Bronchi | 3 | 2019 | 229 | 0.830 |
Why?
|
| Antitubercular Agents | 5 | 2023 | 54 | 0.830 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2021 | 2 | 0.780 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2021 | 10 | 0.770 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2021 | 17 | 0.770 |
Why?
|
| NF-kappa B | 1 | 2024 | 465 | 0.750 |
Why?
|
| Disease Models, Animal | 18 | 2022 | 2350 | 0.750 |
Why?
|
| Epithelial Cells | 4 | 2021 | 688 | 0.750 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2022 | 46 | 0.750 |
Why?
|
| Neutrophils | 5 | 2024 | 308 | 0.740 |
Why?
|
| Lung Diseases | 2 | 2022 | 269 | 0.740 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 135 | 0.730 |
Why?
|
| B-Lymphocytes | 4 | 2023 | 738 | 0.720 |
Why?
|
| Macrophage Activation | 6 | 2024 | 49 | 0.720 |
Why?
|
| Simian Immunodeficiency Virus | 7 | 2022 | 17 | 0.700 |
Why?
|
| Immunologic Memory | 5 | 2021 | 162 | 0.680 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2019 | 20 | 0.670 |
Why?
|
| Respiratory Tract Infections | 3 | 2022 | 106 | 0.670 |
Why?
|
| Granuloma, Respiratory Tract | 3 | 2013 | 4 | 0.660 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 34 | 0.640 |
Why?
|
| Cell Wall | 2 | 2018 | 66 | 0.630 |
Why?
|
| Receptors, CXCR5 | 4 | 2019 | 6 | 0.630 |
Why?
|
| Mycobacterium abscessus | 1 | 2018 | 2 | 0.620 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 49 | 0.620 |
Why?
|
| Aspergillus fumigatus | 1 | 2018 | 18 | 0.610 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 27 | 0.610 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 199 | 0.600 |
Why?
|
| Aspergillosis | 1 | 2018 | 41 | 0.600 |
Why?
|
| Germinal Center | 2 | 2023 | 55 | 0.600 |
Why?
|
| Glycolipids | 1 | 2017 | 29 | 0.600 |
Why?
|
| Lymphocytes | 5 | 2024 | 471 | 0.560 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 249 | 0.550 |
Why?
|
| Protein Subunits | 3 | 2006 | 123 | 0.530 |
Why?
|
| Interferon-gamma | 6 | 2011 | 451 | 0.520 |
Why?
|
| Adaptive Immunity | 7 | 2021 | 167 | 0.500 |
Why?
|
| Immunity, Cellular | 4 | 2020 | 178 | 0.500 |
Why?
|
| Lymphotoxin-alpha | 3 | 2017 | 44 | 0.500 |
Why?
|
| Myeloid Cells | 6 | 2022 | 100 | 0.500 |
Why?
|
| Interleukin-10 | 3 | 2021 | 151 | 0.500 |
Why?
|
| Female | 33 | 2024 | 45954 | 0.500 |
Why?
|
| Chemokine CCL19 | 4 | 2011 | 10 | 0.490 |
Why?
|
| Male | 29 | 2024 | 42191 | 0.490 |
Why?
|
| Cryptococcus neoformans | 3 | 2020 | 9 | 0.470 |
Why?
|
| Respiratory Mucosa | 1 | 2014 | 88 | 0.470 |
Why?
|
| Mice, Transgenic | 10 | 2021 | 1573 | 0.470 |
Why?
|
| Cells, Cultured | 12 | 2022 | 2880 | 0.470 |
Why?
|
| Tularemia | 2 | 2013 | 8 | 0.460 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 50 | 0.460 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2024 | 45 | 0.460 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 42 | 0.450 |
Why?
|
| Mexico | 4 | 2021 | 68 | 0.440 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 105 | 0.440 |
Why?
|
| Communicable Diseases | 1 | 2014 | 63 | 0.440 |
Why?
|
| Bone Marrow | 3 | 2024 | 445 | 0.430 |
Why?
|
| Immunity | 4 | 2022 | 141 | 0.430 |
Why?
|
| Lipocalins | 1 | 2012 | 35 | 0.430 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 37 | 0.430 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 92 | 0.420 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 61 | 0.420 |
Why?
|
| Periodontitis | 1 | 2012 | 7 | 0.420 |
Why?
|
| Alveolar Bone Loss | 1 | 2012 | 20 | 0.420 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 704 | 0.410 |
Why?
|
| Drug Discovery | 1 | 2013 | 107 | 0.410 |
Why?
|
| Th2 Cells | 5 | 2021 | 147 | 0.410 |
Why?
|
| T-Lymphocytes | 6 | 2022 | 1222 | 0.400 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 168 | 0.400 |
Why?
|
| Interleukin-12 Receptor beta 1 Subunit | 1 | 2011 | 2 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 31 | 0.380 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 26 | 0.380 |
Why?
|
| Interferons | 2 | 2022 | 124 | 0.380 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2010 | 9 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 363 | 0.370 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 1429 | 0.370 |
Why?
|
| Health Status Indicators | 1 | 2011 | 103 | 0.370 |
Why?
|
| Cryptococcosis | 3 | 2020 | 11 | 0.360 |
Why?
|
| Health Surveys | 1 | 2011 | 240 | 0.360 |
Why?
|
| Immunity, Active | 1 | 2010 | 9 | 0.360 |
Why?
|
| Chemokine CCL21 | 1 | 2009 | 16 | 0.350 |
Why?
|
| Antigens, Bacterial | 3 | 2017 | 135 | 0.350 |
Why?
|
| Lymphocyte Cooperation | 1 | 2009 | 5 | 0.340 |
Why?
|
| Psychometrics | 1 | 2011 | 329 | 0.340 |
Why?
|
| Gene Expression | 3 | 2021 | 1310 | 0.330 |
Why?
|
| Homeostasis | 2 | 2019 | 412 | 0.330 |
Why?
|
| Carrier Proteins | 1 | 2012 | 680 | 0.320 |
Why?
|
| Mutation | 4 | 2024 | 4126 | 0.310 |
Why?
|
| Adult | 12 | 2024 | 26473 | 0.310 |
Why?
|
| HIV Infections | 5 | 2021 | 834 | 0.310 |
Why?
|
| Influenza A virus | 2 | 2022 | 169 | 0.300 |
Why?
|
| Transcriptome | 3 | 2021 | 628 | 0.280 |
Why?
|
| Toll-Like Receptor 2 | 4 | 2017 | 35 | 0.270 |
Why?
|
| Virulence | 4 | 2022 | 278 | 0.270 |
Why?
|
| Aged | 10 | 2021 | 19044 | 0.270 |
Why?
|
| Macrophages, Alveolar | 2 | 2019 | 57 | 0.270 |
Why?
|
| Disease Progression | 2 | 2021 | 1484 | 0.260 |
Why?
|
| Young Adult | 6 | 2021 | 6280 | 0.260 |
Why?
|
| Middle Aged | 12 | 2021 | 25826 | 0.260 |
Why?
|
| Pandemics | 2 | 2021 | 771 | 0.250 |
Why?
|
| CD11 Antigens | 1 | 2024 | 15 | 0.240 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 153 | 0.240 |
Why?
|
| Pneumocystis | 2 | 2017 | 4 | 0.240 |
Why?
|
| I-kappa B Kinase | 1 | 2024 | 41 | 0.240 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 3 | 2022 | 56 | 0.240 |
Why?
|
| Luminescent Measurements | 1 | 2024 | 62 | 0.230 |
Why?
|
| Prospective Studies | 3 | 2021 | 4265 | 0.230 |
Why?
|
| Antigens, CD | 2 | 2016 | 466 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1702 | 0.230 |
Why?
|
| Bone Marrow Cells | 2 | 2023 | 262 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2024 | 75 | 0.230 |
Why?
|
| ADP-Ribosylation | 1 | 2023 | 2 | 0.230 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 73 | 0.220 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 31 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 50 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 321 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 149 | 0.220 |
Why?
|
| Poliomyelitis | 1 | 2022 | 28 | 0.210 |
Why?
|
| Transforming Growth Factors | 1 | 2022 | 12 | 0.210 |
Why?
|
| Hematopoiesis | 1 | 2023 | 165 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 2334 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2021 | 1533 | 0.210 |
Why?
|
| Cluster Analysis | 1 | 2023 | 371 | 0.210 |
Why?
|
| Integrins | 1 | 2022 | 78 | 0.210 |
Why?
|
| HIV-1 | 2 | 2020 | 165 | 0.200 |
Why?
|
| Transcription Factors | 2 | 2023 | 1650 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2019 | 1649 | 0.200 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2021 | 7 | 0.200 |
Why?
|
| Enterococcus faecalis | 1 | 2022 | 54 | 0.190 |
Why?
|
| Cell Degranulation | 1 | 2021 | 14 | 0.190 |
Why?
|
| Giant Cells | 1 | 2021 | 19 | 0.190 |
Why?
|
| Mice, 129 Strain | 2 | 2021 | 56 | 0.190 |
Why?
|
| Sickness Impact Profile | 1 | 2001 | 26 | 0.190 |
Why?
|
| Monkey Diseases | 1 | 2020 | 9 | 0.190 |
Why?
|
| DNA Repair | 1 | 2023 | 361 | 0.190 |
Why?
|
| Callithrix | 1 | 2020 | 12 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2014 | 690 | 0.190 |
Why?
|
| Xylose | 1 | 2020 | 23 | 0.180 |
Why?
|
| Papio | 1 | 2020 | 82 | 0.180 |
Why?
|
| Mitochondria | 2 | 2022 | 551 | 0.180 |
Why?
|
| Immunophenotyping | 1 | 2021 | 217 | 0.180 |
Why?
|
| Lung Diseases, Fungal | 1 | 2020 | 18 | 0.180 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.180 |
Why?
|
| CD11b Antigen | 1 | 2020 | 36 | 0.180 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2020 | 73 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 34 | 0.180 |
Why?
|
| Stroke Rehabilitation | 1 | 2001 | 41 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 504 | 0.180 |
Why?
|
| Interleukin-1beta | 2 | 2024 | 81 | 0.180 |
Why?
|
| Species Specificity | 2 | 2020 | 684 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2013 | 87 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 80 | 0.170 |
Why?
|
| Macaca | 1 | 2020 | 89 | 0.170 |
Why?
|
| Monocytes | 1 | 2021 | 216 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 46 | 0.170 |
Why?
|
| Activities of Daily Living | 1 | 2001 | 207 | 0.170 |
Why?
|
| Time Factors | 4 | 2019 | 5318 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2017 | 948 | 0.170 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Prognosis | 3 | 2021 | 3770 | 0.160 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 169 | 0.160 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2018 | 11 | 0.160 |
Why?
|
| Interleukin-1 | 1 | 2018 | 72 | 0.160 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 47 | 0.160 |
Why?
|
| Stem Cells | 1 | 2021 | 372 | 0.160 |
Why?
|
| Adolescent | 4 | 2021 | 9226 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2021 | 337 | 0.160 |
Why?
|
| Tuberculoma | 1 | 2017 | 2 | 0.150 |
Why?
|
| Antigen Presentation | 2 | 2016 | 215 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2017 | 1 | 0.150 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1974 | 0.150 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2011 | 0.150 |
Why?
|
| Models, Immunological | 2 | 2009 | 81 | 0.150 |
Why?
|
| Mycobacterium leprae | 1 | 2017 | 6 | 0.150 |
Why?
|
| Interferon-beta | 1 | 2018 | 126 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2399 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2017 | 86 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 578 | 0.150 |
Why?
|
| Tryptophan | 1 | 2017 | 92 | 0.150 |
Why?
|
| Child | 3 | 2024 | 7139 | 0.150 |
Why?
|
| Pneumocystis Infections | 1 | 2017 | 3 | 0.150 |
Why?
|
| Virus Activation | 1 | 2017 | 41 | 0.150 |
Why?
|
| Jordan | 2 | 2011 | 10 | 0.140 |
Why?
|
| Leprosy | 1 | 2016 | 8 | 0.140 |
Why?
|
| Integrin alpha Chains | 1 | 2016 | 16 | 0.140 |
Why?
|
| Infant | 1 | 2024 | 3141 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 115 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 271 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 136 | 0.140 |
Why?
|
| Indians, North American | 1 | 2016 | 47 | 0.140 |
Why?
|
| Succinate Dehydrogenase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2024 | 3708 | 0.140 |
Why?
|
| Succinates | 1 | 2016 | 21 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 155 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1796 | 0.140 |
Why?
|
| Schistosoma mansoni | 1 | 2015 | 17 | 0.130 |
Why?
|
| Schistosomiasis mansoni | 1 | 2015 | 9 | 0.130 |
Why?
|
| Arginase | 1 | 2015 | 16 | 0.130 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2016 | 62 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2022 | 26 | 0.130 |
Why?
|
| Sigma Factor | 1 | 2015 | 23 | 0.130 |
Why?
|
| Cell Differentiation | 4 | 2024 | 1521 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2016 | 227 | 0.130 |
Why?
|
| Regulon | 1 | 2015 | 17 | 0.130 |
Why?
|
| Fungal Proteins | 1 | 2016 | 141 | 0.130 |
Why?
|
| Vaccines, DNA | 1 | 2015 | 18 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2011 | 548 | 0.120 |
Why?
|
| Th1-Th2 Balance | 1 | 2014 | 4 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6767 | 0.120 |
Why?
|
| Hypoxia | 2 | 2022 | 650 | 0.120 |
Why?
|
| Receptors, Interleukin-17 | 2 | 2017 | 10 | 0.120 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 5 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 397 | 0.120 |
Why?
|
| Chemotaxis | 1 | 2014 | 73 | 0.120 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2014 | 13 | 0.120 |
Why?
|
| Intracellular Space | 1 | 2014 | 38 | 0.120 |
Why?
|
| Cytoprotection | 1 | 2014 | 47 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 2857 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2015 | 213 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Aerosols | 3 | 2015 | 44 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 374 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 2013 | 59 | 0.110 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 313 | 0.110 |
Why?
|
| Oropharynx | 1 | 2012 | 15 | 0.110 |
Why?
|
| Enterotoxins | 1 | 2013 | 21 | 0.110 |
Why?
|
| Chemokine CXCL9 | 1 | 2012 | 8 | 0.110 |
Why?
|
| Candida albicans | 1 | 2012 | 32 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 37 | 0.110 |
Why?
|
| Siderophores | 1 | 2012 | 22 | 0.110 |
Why?
|
| Candidiasis | 1 | 2012 | 37 | 0.110 |
Why?
|
| Mouth Mucosa | 1 | 2012 | 67 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2013 | 199 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 148 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2013 | 91 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2014 | 446 | 0.100 |
Why?
|
| Iron | 1 | 2012 | 165 | 0.100 |
Why?
|
| Asthma | 1 | 2020 | 976 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2013 | 279 | 0.100 |
Why?
|
| Receptors, CCR7 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 121 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 167 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 921 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 1241 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 181 | 0.100 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Chlamydia muridarum | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2010 | 29 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 839 | 0.090 |
Why?
|
| Salmonella typhimurium | 1 | 2010 | 32 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 285 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 163 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2010 | 44 | 0.090 |
Why?
|
| Viral Load | 2 | 2020 | 145 | 0.090 |
Why?
|
| Lymphocyte Depletion | 2 | 2020 | 98 | 0.090 |
Why?
|
| Vaccines, Attenuated | 2 | 2021 | 51 | 0.090 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 272 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2009 | 47 | 0.080 |
Why?
|
| Risk Factors | 1 | 2020 | 5463 | 0.080 |
Why?
|
| Interleukin-23 Subunit p19 | 2 | 2006 | 7 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1852 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 155 | 0.080 |
Why?
|
| Yersinia pestis | 1 | 2008 | 24 | 0.080 |
Why?
|
| Plague | 1 | 2008 | 27 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1147 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 269 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2009 | 291 | 0.080 |
Why?
|
| Bacterial Load | 2 | 2020 | 18 | 0.070 |
Why?
|
| HIV | 2 | 2017 | 48 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2008 | 213 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2014 | 0.070 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2005 | 1 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 42 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 699 | 0.060 |
Why?
|
| Receptors, Cytokine | 1 | 2004 | 28 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 126 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 145 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2752 | 0.060 |
Why?
|
| Luminescence | 1 | 2024 | 21 | 0.060 |
Why?
|
| Luciferases | 1 | 2024 | 127 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2024 | 98 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 666 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2005 | 519 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 294 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 205 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1763 | 0.060 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2022 | 4 | 0.050 |
Why?
|
| Child Mortality | 1 | 2022 | 6 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2022 | 24 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 2439 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 77 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 1086 | 0.050 |
Why?
|
| Immunity, Heterologous | 1 | 2021 | 1 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 85 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 31 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 397 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2021 | 18 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2021 | 13 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 102 | 0.050 |
Why?
|
| Rehabilitation Centers | 1 | 2001 | 8 | 0.050 |
Why?
|
| Occupational Therapy | 1 | 2001 | 16 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2021 | 66 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2020 | 27 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 145 | 0.050 |
Why?
|
| Trehalose | 1 | 2020 | 4 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 124 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 421 | 0.050 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2020 | 18 | 0.050 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 30 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2021 | 123 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2001 | 83 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2001 | 140 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 235 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 100 | 0.040 |
Why?
|
| Probability | 1 | 2001 | 353 | 0.040 |
Why?
|
| Lentivirus | 1 | 2019 | 43 | 0.040 |
Why?
|
| Biological Transport | 1 | 2020 | 400 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1011 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2019 | 30 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 2019 | 35 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 293 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2001 | 292 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 308 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 420 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 463 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 475 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1066 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2024 | 574 | 0.040 |
Why?
|
| Proteomics | 1 | 2019 | 230 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 308 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 190 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 48 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2017 | 38 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 85 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 170 | 0.040 |
Why?
|
| Dimerization | 2 | 2008 | 143 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 638 | 0.040 |
Why?
|
| Succinic Acid | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2016 | 18 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 376 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 555 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 232 | 0.030 |
Why?
|
| Melanins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 478 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2495 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1837 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 140 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 293 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 685 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2289 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 2013 | 14 | 0.030 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2017 | 537 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 487 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 307 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 1135 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 181 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 824 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 542 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 131 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 477 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2011 | 70 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2011 | 32 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2011 | 58 | 0.020 |
Why?
|
| Stroke | 1 | 2001 | 982 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 637 | 0.020 |
Why?
|
| Pneumocystis carinii | 1 | 2010 | 3 | 0.020 |
Why?
|
| beta-Glucans | 1 | 2010 | 5 | 0.020 |
Why?
|
| Immune Sera | 1 | 2010 | 52 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2010 | 132 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 99 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 261 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1212 | 0.020 |
Why?
|
| Pneumonia | 1 | 2011 | 182 | 0.020 |
Why?
|
| Lipid A | 1 | 2008 | 3 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 8188 | 0.020 |
Why?
|
| Insect Vectors | 1 | 2008 | 10 | 0.020 |
Why?
|
| Siphonaptera | 1 | 2008 | 8 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2008 | 41 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 210 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 132 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 208 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2010 | 275 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1527 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2008 | 183 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2001 | 8990 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1485 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 42 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3026 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2008 | 605 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 1181 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2004 | 39 | 0.020 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 36 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 98 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 88 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 234 | 0.010 |
Why?
|